211 related articles for article (PubMed ID: 26542126)
1. Effects of Thiazolidinediones on metabolism and cancer: Relative influence of PPARγ and IGF-1 signaling.
Mughal A; Kumar D; Vikram A
Eur J Pharmacol; 2015 Dec; 768():217-25. PubMed ID: 26542126
[TBL] [Abstract][Full Text] [Related]
2. Thiazolidinediones up-regulate insulin-like growth factor-1 receptor via a peroxisome proliferator-activated receptor gamma-independent pathway.
Higashi Y; Holder K; Delafontaine P
J Biol Chem; 2010 Nov; 285(47):36361-8. PubMed ID: 20843793
[TBL] [Abstract][Full Text] [Related]
3. Beyond peroxisome proliferator-activated receptor gamma signaling: the multi-facets of the antitumor effect of thiazolidinediones.
Weng JR; Chen CY; Pinzone JJ; Ringel MD; Chen CS
Endocr Relat Cancer; 2006 Jun; 13(2):401-13. PubMed ID: 16728570
[TBL] [Abstract][Full Text] [Related]
4. Antitumor effects of energy restriction-mimetic agents: thiazolidinediones.
Omar HA; Salama SA; Arafa el-SA; Weng JR
Biol Chem; 2013 Jul; 394(7):865-70. PubMed ID: 23612598
[TBL] [Abstract][Full Text] [Related]
5. Peroxisome proliferator-activated receptor gamma-independent activation of p38 MAPK by thiazolidinediones involves calcium/calmodulin-dependent protein kinase II and protein kinase R: correlation with endoplasmic reticulum stress.
Gardner OS; Shiau CW; Chen CS; Graves LM
J Biol Chem; 2005 Mar; 280(11):10109-18. PubMed ID: 15649892
[TBL] [Abstract][Full Text] [Related]
6. Peroxisome proliferator-activated receptor gamma-independent effects of thiazolidinediones on human cardiac myofibroblast function.
Mughal RS; Warburton P; O'Regan DJ; Ball SG; Turner NA; Porter KE
Clin Exp Pharmacol Physiol; 2009 May; 36(5-6):478-86. PubMed ID: 19673929
[TBL] [Abstract][Full Text] [Related]
7. A selective peroxisome proliferator-activated receptor-gamma modulator, telmisartan, binds to the receptor in a different fashion from thiazolidinediones.
Tagami T; Yamamoto H; Moriyama K; Sawai K; Usui T; Shimatsu A; Naruse M
Endocrinology; 2009 Feb; 150(2):862-70. PubMed ID: 19147680
[TBL] [Abstract][Full Text] [Related]
8. [Anti-cancer action by PPARgamma ligand].
Okumura T
Nihon Rinsho; 2010 Feb; 68(2):267-72. PubMed ID: 20158095
[TBL] [Abstract][Full Text] [Related]
9. Peroxisome proliferator-activated receptor-gamma in lung cancer: defining specific versus "off-target" effectors.
Nemenoff RA
J Thorac Oncol; 2007 Nov; 2(11):989-92. PubMed ID: 17975488
[TBL] [Abstract][Full Text] [Related]
10. Energy restriction mimetic agents to target cancer cells: comparison between 2-deoxyglucose and thiazolidinediones.
Kuntz S; Mazerbourg S; Boisbrun M; Cerella C; Diederich M; Grillier-Vuissoz I; Flament S
Biochem Pharmacol; 2014 Nov; 92(1):102-11. PubMed ID: 25083915
[TBL] [Abstract][Full Text] [Related]
11. Peroxisome proliferator-activated receptor gamma (PPARgamma): Is the genomic activity the only answer?
Luconi M; Cantini G; Serio M
Steroids; 2010; 75(8-9):585-94. PubMed ID: 19900469
[TBL] [Abstract][Full Text] [Related]
12. PPARgamma activation by thiazolidinediones (TZDs) may modulate breast carcinoma outcome: the importance of interplay with TGFbeta signalling.
Jarrar MH; Baranova A
J Cell Mol Med; 2007; 11(1):71-87. PubMed ID: 17367502
[TBL] [Abstract][Full Text] [Related]
13. [Recent trends in PPARgamma agonist development of thiazolidinediones and non-thiazolidinediones].
Tanaka T
Nihon Rinsho; 2010 Feb; 68(2):249-55. PubMed ID: 20158092
[TBL] [Abstract][Full Text] [Related]
14. Thiazolidinediones enhance sodium-coupled bicarbonate absorption from renal proximal tubules via PPARγ-dependent nongenomic signaling.
Endo Y; Suzuki M; Yamada H; Horita S; Kunimi M; Yamazaki O; Shirai A; Nakamura M; Iso-O N; Li Y; Hara M; Tsukamoto K; Moriyama N; Kudo A; Kawakami H; Yamauchi T; Kubota N; Kadowaki T; Kume H; Enomoto Y; Homma Y; Seki G; Fujita T
Cell Metab; 2011 May; 13(5):550-61. PubMed ID: 21531337
[TBL] [Abstract][Full Text] [Related]
15. Chemotherapy and chemoprevention by thiazolidinediones.
Fröhlich E; Wahl R
Biomed Res Int; 2015; 2015():845340. PubMed ID: 25866814
[TBL] [Abstract][Full Text] [Related]
16. Targeting glioblastoma stem cells (GSCs) with peroxisome proliferator-activated receptor gamma (PPARγ) ligands.
Im CN
IUBMB Life; 2016 Mar; 68(3):173-7. PubMed ID: 26818439
[TBL] [Abstract][Full Text] [Related]
17. Thiazolidinediones/PPARγ agonists and fatty acid synthase inhibitors as an experimental combination therapy for prostate cancer.
Mansour M; Schwartz D; Judd R; Akingbemi B; Braden T; Morrison E; Dennis J; Bartol F; Hazi A; Napier I; Abdel-Mageed AB
Int J Oncol; 2011 Feb; 38(2):537-46. PubMed ID: 21170507
[TBL] [Abstract][Full Text] [Related]
18. Rosiglitazone attenuates insulin-like growth factor 1 receptor survival signaling in PC-3 cells.
Papageorgiou E; Pitulis N; Manoussakis M; Lembessis P; Koutsilieris M
Mol Med; 2008; 14(7-8):403-11. PubMed ID: 18475308
[TBL] [Abstract][Full Text] [Related]
19. Thiazolidinediones and PPARγ agonists: time for a reassessment.
Cariou B; Charbonnel B; Staels B
Trends Endocrinol Metab; 2012 May; 23(5):205-15. PubMed ID: 22513163
[TBL] [Abstract][Full Text] [Related]
20. Diabetes: New conductors for the peroxisome proliferator-activated receptor γ (PPARγ) orchestra.
Whitehead JP
Int J Biochem Cell Biol; 2011 Aug; 43(8):1071-4. PubMed ID: 21558015
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
